User login
Dr Anca Askanase, director of the Lupus Center at Columbia University Medical Center, highlights the latest research on systemic lupus erythematosus (SLE) and lupus nephritis from the American College of Rheumatology (ACR) 2022.
Dr Askanase first discusses a small study using autologous chimeric antigen receptor T-cell (CAR-T) therapy, which is approved for use in several blood cancers, as an alternative for patients with refractory SLE. Five patients received CAR-T cells, and all achieved sustained, drug-free remission.
Next, Dr Askanase highlights a phase 2B study evaluating the tyrosine kinase 2 inhibitor deucravacitinib in patients with SLE. In early results, patients taking deucravacitinib showed a statistically meaningful response in disease activity compared with placebo.
She then summarizes her presentation on oral cenerimod. The phase 2, 12-week study demonstrated that cenerimod reduced total lymphocyte count compared with placebo in SLE patients.
Next, Dr Askanase details the long-term extension of the TULIP trials. Researchers found that anifrolumab has a favorable benefit-risk profile when compared with placebo and is therefore a possible long-term treatment option for patients with moderate to severe SLE.
Finally, Dr Askanase discusses the positive findings from the phase 3 AURORA 1 and AURORA 2 studies, which sought to determine whether the addition of voclosporin to mycophenolate mofetil and low-dose steroids could maintain the reduction in proteinuria in patients with lupus nephritis.
--
Anca Askanase, MD, MPH, Professor of Medicine, Director, Lupus Center, Department of Rheumatology, Columbia University Medical Center, New York, New York
Anca Askanase, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Bristol Myers Squibb; Celgene; Eli Lilly; GSK; Idorsia; Janssen; Pfizer
Received income in an amount equal to or greater than $250 from: AstraZeneca; Bristol Myers Squibb; Celgene; Eli Lilly; GSK; Idorsia; Janssen; Pfizer
Dr Anca Askanase, director of the Lupus Center at Columbia University Medical Center, highlights the latest research on systemic lupus erythematosus (SLE) and lupus nephritis from the American College of Rheumatology (ACR) 2022.
Dr Askanase first discusses a small study using autologous chimeric antigen receptor T-cell (CAR-T) therapy, which is approved for use in several blood cancers, as an alternative for patients with refractory SLE. Five patients received CAR-T cells, and all achieved sustained, drug-free remission.
Next, Dr Askanase highlights a phase 2B study evaluating the tyrosine kinase 2 inhibitor deucravacitinib in patients with SLE. In early results, patients taking deucravacitinib showed a statistically meaningful response in disease activity compared with placebo.
She then summarizes her presentation on oral cenerimod. The phase 2, 12-week study demonstrated that cenerimod reduced total lymphocyte count compared with placebo in SLE patients.
Next, Dr Askanase details the long-term extension of the TULIP trials. Researchers found that anifrolumab has a favorable benefit-risk profile when compared with placebo and is therefore a possible long-term treatment option for patients with moderate to severe SLE.
Finally, Dr Askanase discusses the positive findings from the phase 3 AURORA 1 and AURORA 2 studies, which sought to determine whether the addition of voclosporin to mycophenolate mofetil and low-dose steroids could maintain the reduction in proteinuria in patients with lupus nephritis.
--
Anca Askanase, MD, MPH, Professor of Medicine, Director, Lupus Center, Department of Rheumatology, Columbia University Medical Center, New York, New York
Anca Askanase, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Bristol Myers Squibb; Celgene; Eli Lilly; GSK; Idorsia; Janssen; Pfizer
Received income in an amount equal to or greater than $250 from: AstraZeneca; Bristol Myers Squibb; Celgene; Eli Lilly; GSK; Idorsia; Janssen; Pfizer
Dr Anca Askanase, director of the Lupus Center at Columbia University Medical Center, highlights the latest research on systemic lupus erythematosus (SLE) and lupus nephritis from the American College of Rheumatology (ACR) 2022.
Dr Askanase first discusses a small study using autologous chimeric antigen receptor T-cell (CAR-T) therapy, which is approved for use in several blood cancers, as an alternative for patients with refractory SLE. Five patients received CAR-T cells, and all achieved sustained, drug-free remission.
Next, Dr Askanase highlights a phase 2B study evaluating the tyrosine kinase 2 inhibitor deucravacitinib in patients with SLE. In early results, patients taking deucravacitinib showed a statistically meaningful response in disease activity compared with placebo.
She then summarizes her presentation on oral cenerimod. The phase 2, 12-week study demonstrated that cenerimod reduced total lymphocyte count compared with placebo in SLE patients.
Next, Dr Askanase details the long-term extension of the TULIP trials. Researchers found that anifrolumab has a favorable benefit-risk profile when compared with placebo and is therefore a possible long-term treatment option for patients with moderate to severe SLE.
Finally, Dr Askanase discusses the positive findings from the phase 3 AURORA 1 and AURORA 2 studies, which sought to determine whether the addition of voclosporin to mycophenolate mofetil and low-dose steroids could maintain the reduction in proteinuria in patients with lupus nephritis.
--
Anca Askanase, MD, MPH, Professor of Medicine, Director, Lupus Center, Department of Rheumatology, Columbia University Medical Center, New York, New York
Anca Askanase, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AstraZeneca; Bristol Myers Squibb; Celgene; Eli Lilly; GSK; Idorsia; Janssen; Pfizer
Received income in an amount equal to or greater than $250 from: AstraZeneca; Bristol Myers Squibb; Celgene; Eli Lilly; GSK; Idorsia; Janssen; Pfizer
